1.0MedCity Newshttps://medcitynews.comFrank Vinluanhttps://medcitynews.com/author/fvinluan/BioCryst’s $700M Astria Acquisition Gives It a Shot to Beat Larger Rivals in Rare Disease HAE - MedCity Newsrich600338<blockquote class="wp-embedded-content" data-secret="NE3xVhVqzC"><a href="https://medcitynews.com/2025/10/biocryst-astria-acquisition-hereditary-angioedema-rare-disease-hae-navenibart-bcrx-atxs/">BioCryst’s $700M Astria Acquisition Gives It a Shot to Beat Larger Rivals in Rare Disease HAE</a></blockquote><iframe sandbox="allow-scripts" security="restricted" src="https://medcitynews.com/2025/10/biocryst-astria-acquisition-hereditary-angioedema-rare-disease-hae-navenibart-bcrx-atxs/embed/#?secret=NE3xVhVqzC" width="600" height="338" title="“BioCryst’s $700M Astria Acquisition Gives It a Shot to Beat Larger Rivals in Rare Disease HAE” — MedCity News" data-secret="NE3xVhVqzC" frameborder="0" marginwidth="0" marginheight="0" scrolling="no" class="wp-embedded-content"></iframe><script type="text/javascript">
/* <![CDATA[ */
/*! This file is auto-generated */
!function(d,l){"use strict";l.querySelector&&d.addEventListener&&"undefined"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!/[^a-zA-Z0-9]/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret="'+t.secret+'"]'),o=l.querySelectorAll('blockquote[data-secret="'+t.secret+'"]'),c=new RegExp("^https?:$","i"),i=0;i<o.length;i++)o[i].style.display="none";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute("style"),"height"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):"link"===t.message&&(r=new URL(s.getAttribute("src")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener("message",d.wp.receiveEmbedMessage,!1),l.addEventListener("DOMContentLoaded",function(){for(var e,t,s=l.querySelectorAll("iframe.wp-embedded-content"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute("data-secret"))||(t=Math.random().toString(36).substring(2,12),e.src+="#?secret="+t,e.setAttribute("data-secret",t)),e.contentWindow.postMessage({message:"ready",secret:t},"*")},!1)))}(window,document);
/* ]]> */
</script>
https://medcitynews.com/wp-content/uploads/sites/7/2023/06/GettyImages-1161382041.jpg724483BioCryst Pharmaceuticals’ Astria Therapeutics acquisition brings navenibart, a drug in Phase 3 testing for the rare disease hereditary angioedema. The injectable antibody has the potential to match the efficacy of the blockbuster Takeda Pharmaceutical drug that currently dominates the market, but with less burdensome dosing that could encourage HAE patients to switch.